Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima®) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts

Cancer Chemotherapy and Pharmacology

Volumn 61, Issue 2, 2008, Pages 179-188

  Gustafson, Daniel L ^a,c   Frederick, Barbara ^b,c   Merz, Andrea L ^c   Raben, David ^b,c  

^a USA   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

EGFR; Head and neck cancer; Radiotherapy; Scheduling; Vandetanib; Xenografts

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; VANDETANIB; VASCULOTROPIN RECEPTOR 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER RADIOTHERAPY; CANCER REGRESSION; CELL LINE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; HEAD AND NECK CANCER; IONIZING RADIATION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE; TUMOR XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CELL PROLIFERATION; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASM TRANSPLANTATION; PIPERIDINES; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 36348941014     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0460-5     Document Type: Article

References (48)

1. Vokes EE, Gordon GS (2001) Chemotherapy of head and neck cancer. In: Perry MC (ed) The chemotherapy source book. Lippincott, Williams & Wilkins, New York, pp 610-626
2. El-Sayed S, Nelson N (1996) Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials. J Clin Oncol 14:838-847
3. Cohen EE, Lingen MW, Vokes EE (2004) The expanding role of systemic therapy in head and neck cancer. J Clin Oncol 22:1743-1752
4. Thomas SM, Grandis JR (2004) Pharmacokinetic and pharmacodynamic properties of EGFR inhibitors under clinical investigation. Cancer Treat Rev 30:255-268
5. Grandis JR, Melhem MF, Barnes EL et al (1996) Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 78:1284-1292
6. Grandis JR, Melhem MF, Gooding WE et al (1998) Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832
7. Gupta AK, McKenna WG, Weber CN et al (2002) Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8:885-892
8. Huang SM, Li J, Armstrong EA et al (2002) Modulation of radiation response and tumor-induced angiogenesis after epidermal growth factor receptor inhibition by ZD1839 (Iressa). Cancer Res 62:4300-4306
9. Huang SM, Harari PM (2000) Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 6:2166-2174
10. Ochs JS (2004) Rationale and clinical basis for combining gefitinib (Iressa, ZD1839) with radiation therapy for solid tumors. Int J Radiat Oncol Biol Phys 58:941-949
11. Raben D, Helfrich BA, Chan D et al (2002) ZD1839, a selective epidermal growth factor receptor tyrosine kinase inhibitor, alone and in combination with radiation and chemotherapy as a new therapeutic strategy in non-small cell lung cancer. Sem Oncol 29:37-46
12. Bonner JA, Harari PM, Giralt J et al (2006) Radiotherapy plus Cetuximab for squamous-cell carcinoma of the head and neck. New Engl J Med 354:567-578
13. Dancey JE (2004) Predictive factors for epidermal growth factor receptor inhibitors-the bull's-eye hits the arrow. Cancer Cell 5:411-415
14. Mauceri HJ, Hanna NN, Beckett MA et al (1998) Combined effects of angiostatin and ionizing radiation in antitumor therapy. Nature 394:287-291
15. Wachsberger P, Burd R, Dicker AP (2003) Tumor response to ionizing radiation combined with antiangioenesis or vascular targeting agents: exploring mechanisms of interaction. Clin Cancer Res 9:1957-1971
16. Neufeld G, Cohen T, Gengrinovitch S et al (1999) Vascular endothelial growth factor (VEGF) and its receptors. FASEB J 13:9-22
17. Bold G, Altmann KH, Frei J et al (2000) New anilinophthalazines as potent and orally well absorbed inhibitors of the VEGF receptor tyrosine kinases useful as antagonists of tumor-driven angiogenesis. J Med Chem 43:2310-2323
18. Hennequin LF, Stokes ESE, Thomas AP et al (2002) Novel 4-anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF rreceptor tyrosine kinase inhibitors. J Med Chem 45:1300-1312
19. Gupta VK, Jaskowiak NT, Beckett MA et al (2002) Vascular endothelial growth factor enhances endothelial cell survival and tumor radioresistance. Cancer J 8:47-54
20. Abdollahi A, Lipson KE, Han X et al (2003) SU5416 and SU6668 attenuate the angiogenic effects of radiation-induced tumor cell growth factor production and amplify the direct anti-endothelial action of radiation in vitro. Cancer Res 63:3755-3763
21. Geng L, Donnelly E, McMahon G et al (2001) Inhibition of vascular endothelial growth factor receptor signaling leads to reversal of tumor resistance to radiotherapy. Cancer Res 61:2413-2419
22. Lee CG, Heijn M, di Tomaso E et al (2000) Anti-vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 60:5565-5570
23. Gorski DH, Beckett MA, Jaskowiak NT et al (1999) Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 59:3374-3378
24. ®) in tumor bearing nude mice following oral dosing. J Pharmacol Exp Ther 318:872-880
25. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
26. Hall EJ (2000) Radiosensitivity and cell age in the mitotic cycle. In: Hall EJ (ed) Radiobiology for the radiologist. Lippincott, Williams & Wilkins, New York, pp 51-66
27. Ciardiello F, Caputo R, Bianco R et al (2001) Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth receptor tyrosine kinase inhibitor. Clin Cancer Res 7:1459-1465
28. Alvi A, Johnson JT (1997) Development of distant metastasis after treatment of advanced-stage head and neck cancer. Head Neck 19:500-505
29. Brown JS, Lowe D, Kalavrezos N et al (2002) Patterns of invasion and routes of tumor entry into the mandible by oral squamous cell carcinoma. Head Neck 24:370-383
30. Ang KK, Berkey BA, Tu X et al (2002) Impact of epidermal growth factor receptor on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62:7350-7356
31. Chung CH, Parker JS, Karaca G et al (2004) Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 5:489-500
32. Tong RT, Boucher Y, Kozin SV et al (2004) Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 64:3731-3736
33. Winkler F, Kozin SV, Tong RT et al (2004) Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 6:553-563
34. Beaudry P, Force J, Naumov GN et al (2005) Differential effects of vascular endothelial growth factor receptor-2 inhibitor ZD6474 on circulating endothelial progenitors and mature circulating endothelial cells: implications for use as a surrogate marker of antiangiogenic activity. Clin Cancer Res 11:3514-3522
35. Garcia-Barros M, Paris F, Cordon-Cardo C et al (2003) Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300:1155-1159
36. Bianco C, Tortora G, Bianco R et al (2002) Enhancement of antitumor activity of ionizing radiation by combined treatment with the selective epidermal growth factor receptor-tyrosine kinase inhibitor ZD1839 (Iressa). Clin Cancer Res 8:3250-3258
37. Magné N, Fischel JL, Tiffon C et al (2003) Molecular mechanism underlying the interaction between ZD1839 ('Iressa') and cisplatin/5- fluorouracil. Br J Cancer 89:585-592
38. Kumar P, Miller AI, Polverini PJ (2004) p38 MAPK mediates γ-irradiation-induced endothelial cell apoptosis, and vascular endothelial growth factor protects endothelial cells through the phosphoinositide 3-kinase-Akt-Bcl-2 pathway. J Biol Chem 279:43352-43360
39. Zingg D, Riesterer O, Fabbro D et al (2004) Differential activation of the phosphatidylinositol 3′-kinase/Akt survival pathway by ionizing radiation in tumor and primary endothelial cells. Cancer Res 64:5398-5406
40. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
41. Bischof M, Abdollahi A, Gong P et al (2004) Triple combination of irradiation, chemotherapy (pemetrexed), and VEGFR inhibition (SU5416) in human endothelial and tumor cells. Int J Radiat Oncol Biol Phys 60:1220-1232
42. Li J, Huang S, Armstrong EA et al (2005) Angiogenesis and radiation response modulation after vascular endothelial growth factor receptor-2 (VEGFR2) blockade. Int J Radiat Oncol Biol Phys 62:1477-1485
43. Zips D, Krause M, Hessel F et al (2003) Experimental study on different combination schedules of VEGF-receptor inhibitor PTK787/ZK222584 and fractionated irradiation. Anticancer Res 23:3869-3876
44. Rofstad EK, Henriksen K, Galappathi K et al (2003) Antiangiogenic treatment with thrombospondin-1 enhances primary tumor radiation response and prevents growth of dormant pulmonary micrometastases after curative radiation therapy in human melanoma xenografts. Cancer Res 63:4055-4061
45. Gorski DH, Mauceri HJ, Salloum RM et al (1998) Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin. Cancer Res 58:5686-5689
46. Williams KJ, Telfer BA, Brave S et al (2004) ZD6474, a potent inhibitor of vascular endothelial growth factor signaling, combined with radiotherapy: schedule-dependent enhancement of antitumor activity. Clin Cancer Res 10:8587-8593
47. Brazelle WD, Shi W, Siemann DW (2006) VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapy. Int J Radiat Oncol Biol Phys 65:836-841
48. Balin-Gauthier D, Delord JP, Rochaix P et al (2006) In vivo and in vitro antitumor activity of oxaliplatin in combination with cetuximab in human colorectal tumor cell lines expressing different level of EGFR. Cancer Chemother Pharmacol 57:709-718